Advertisement

Endocrine Pathology

, Volume 17, Issue 4, pp 377–386 | Cite as

Expression of prolactin receptor and prolactin in normal and malignant thyroid: A tissue microarray study

  • Patricia Costa
  • Ana Luísa Catarino
  • Fernanda Silva
  • Luís G. Sobrinho
  • Maria João BugalhoEmail author
Clinical Research

Abstract

Objective

There is increasing evidence involving prolactin (PRL) and its receptor (PRLR) in the development of different cancers. The aim of the present study was to investigate the expression of PRLR and PRL in human thyroid tissues.

Design and Methods

Using tissue microarray (TMA) by immunohistochemical staining, we examined the expression level of PRLR and PRL in 314 specimens from 71 thyroid cancer patients and 15 normal thyroid samples.

Results

Expression of the PRLR was observed in 93.3% of normal thyroid samples and in 76.1% of all thyroid cancers, while expression of PRL was observed in only 10% of medullary thyroid carcinomas and not at all in the other specimens, whether normal or neoplastic. Moreover, results suggested an overexpression of PRLR in 70% of medullary thyroid carcinomas, whereas 53.3% of poorly differentiated thyroid carcinomas showed a negative pattern of staining (p=0.014 vs normal).

Conclusions

Present data revealed, for the first time, a widespread expression of PRLR in normal and neoplastic human thyroid tissues as well as a scarce expression of PRL, observed only in a few medullary thyroid carcinomas. Whether the overexpression of PRLR observed in medullary thyroid carcinomas or the underexpression of PRLR observed in poorly differentiated thyroid carcinomas play a contributory role in the oncogenesis of these tumors remains to be determined.

Key Words

Medullary thyroid carcinoma prolactin prolactin receptor tissue microarray TMA 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639–669, 1996.PubMedCrossRefGoogle Scholar
  2. 2.
    Bole-Feysor C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225–268, 1998.CrossRefGoogle Scholar
  3. 3.
    Boutin JM, Jolicoeur C, Okamura H, et al. Cloning and expression of the rat prolactin receptor, a member of the growth hormone prolactin receptor gene family. Cell 53:69–77, 1988.PubMedCrossRefGoogle Scholar
  4. 4.
    Bazan JF. A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochem Biophys Res Commun 164:788–795, 1989.PubMedCrossRefGoogle Scholar
  5. 5.
    Kelly PA, Djiane J, Postel-Vinay MC, Edery M. The prolactin/growth hormone receptor family. Endocr Rev 12:235–251, 1991.PubMedGoogle Scholar
  6. 6.
    DeViro WJ, Avakian C, Stone S, Okulicz WC. Prolactin-stimulated mitogenesis of cultured astrocytes is mediated by a protein kinase C-dependent mechanism. J Neurochem 60:832–842, 1993.Google Scholar
  7. 7.
    Leff MA, Buckley DJ, Krumenacker JS, Reed JC, Miyashita T, Buckley AR. Rapid modulation of the apoptosis regulatory genes, bcl-2 and bax by prolactin in rat Nb2 lymphoma cells. Endocrinology 137:5456–5462, 1996.PubMedCrossRefGoogle Scholar
  8. 8.
    Flint DJ, Knight CH. Interactions of prolactin and growth hormone (GH) in the regulation of mammary gland function and epithelial cell survival. J Mammary Gland Biol Neoplasia 2:41–48, 1997.PubMedCrossRefGoogle Scholar
  9. 9.
    Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer 91:305–311, 2004.PubMedGoogle Scholar
  10. 10.
    Asai-Sato M, Nagashima Y, Miyagi E, et al. Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment. Int J Cancer 115:539–544, 2005.PubMedCrossRefGoogle Scholar
  11. 11.
    Clevenger CV, Zhang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/ paracrine loop. Am J Pathol 146:695–705, 1995.PubMedGoogle Scholar
  12. 12.
    Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 55:2591–2595, 1995.PubMedGoogle Scholar
  13. 13.
    Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64:6814–6819, 2004.PubMedCrossRefGoogle Scholar
  14. 14.
    Harvey PW. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments. J Appl Toxicol 25:179–183, 2005.PubMedCrossRefGoogle Scholar
  15. 15.
    Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 100:2744–2751, 1997.PubMedCrossRefGoogle Scholar
  16. 16.
    Wennbo H, Tornell J. The role of prolactin and growth hormone in breast cancer. Oncogene 19:1072–1076, 2000.PubMedCrossRefGoogle Scholar
  17. 17.
    Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces E Ralpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene 22:4664–4674, 2003.PubMedCrossRefGoogle Scholar
  18. 18.
    Bhatavdekar J, Patel D, Ghosh N, et al. Interrelationship of prolactin and its receptor in carcinoma of colon and recrum: a preliminary report. J Surg Oncol 55:246–249, 1994.PubMedCrossRefGoogle Scholar
  19. 19.
    Bhatavdekar JM, Patel DD, Shah NG, et al. Prognostic value of insulin-like growth factor-1 receptors in patients with colon/rectal cancer: correlation with plasma prolactin. Eur J Surg Oncol 21:23–26, 1995.PubMedCrossRefGoogle Scholar
  20. 20.
    Walker AM, Montgomery DW, Saraiya S, et al. Prolactin-immunoglobulin G complexes from human serum act as costimulatory ligands causing proliferation of malignant B lymphocytes. Proc Natl Acad Sci USA 92:3278–3282, 1995.PubMedCrossRefGoogle Scholar
  21. 21.
    Gout PW, Beer CT, Noble RI. Prolactinstimulated growth of cell cultures established from malignant Nb rat lymphomas. Cancer Res 40:2433–2436, 1980.PubMedGoogle Scholar
  22. 22.
    Nishiguchi Y, Hibasami H, Komada Y, Sakurai M, Nakashima K. Human promvelocytic cell line HL60 has the specific binding sites for prolactin and its ornithine decarboxylase, DNA synthesis and cellular proliferation are induced by prolactin. Leuk Res 17:633–637, 1993.PubMedCrossRefGoogle Scholar
  23. 23.
    Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 13:245–250, 2002.PubMedCrossRefGoogle Scholar
  24. 24.
    Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 80:1943–1949, 2000.PubMedGoogle Scholar
  25. 25.
    Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249–2256, 2001.PubMedGoogle Scholar
  26. 26.
    Banerjee R, Ginsburg E, Vonderhaar BK. Characterization of a monoclonal antibody against human prolactin receptors. Int J Cancer 55:712–721, 1993.PubMedCrossRefGoogle Scholar
  27. 27.
    McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716–721, 1985.PubMedGoogle Scholar
  28. 28.
    Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E. Amplification of tissue by construction of tissue microarrays. Exp Mol Pathol 70:255–264, 2001.PubMedCrossRefGoogle Scholar
  29. 29.
    Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 12:27–34, 2003.PubMedCrossRefGoogle Scholar
  30. 30.
    Ginestier C, Charafe-Jauffret E, Bertucci F, et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 161:1223–1233, 2002.PubMedGoogle Scholar
  31. 31.
    Peirce SK, Chen WY, Chen WY. Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. J Endocrinol 171:R1–4, 2001.PubMedCrossRefGoogle Scholar
  32. 32.
    Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 26:400–422, 2005.PubMedCrossRefGoogle Scholar
  33. 33.
    Xu X, Kreye E, Kuo CB, Walker AM. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice. Cancer Res 61:6098–6104, 2001.PubMedGoogle Scholar
  34. 34.
    Otte JM, Otte C, Beckedorf S, et al. Expression of functional prolactin and its receptor in human colorectal cancer. Int J Colorectal Dis 18:86–94, 2003.PubMedCrossRefGoogle Scholar
  35. 35.
    Kedzia C, Lacroix L, Ameur N, et al. Medullary thyroid carcinoma arises in the absence of prolactin signaling. Cancer Res 65:8497–8503, 2005.PubMedCrossRefGoogle Scholar
  36. 36.
    Lu CC, Tsai SC, Huang WJ, Tsai CL, Wang PS. Effects of hyperprolactinemia on calcitonin secretion in male rats. Metabolism 48:221–226, 1999.PubMedCrossRefGoogle Scholar
  37. 37.
    Samaan NA, Anderson GD, Adam-Mayne ME. Immunoreactive calcitonin in the mother, neonate, child and adult. Am J Obstet Gynecol 121:622–625, 1975.PubMedGoogle Scholar
  38. 38.
    Stevenson JC, Hillyard CJ, MacIntyre I. A physiological role for calcitonin: protection of the maternal skeleton. Lancet ii:769–770, 1979.CrossRefGoogle Scholar
  39. 39.
    Whitehead M, Lane G, Young O, et al. Interrelations of calcium-regulating hormones during normal pregnancy. Br Med J 283:10–12, 1981.Google Scholar
  40. 40.
    Dahlman T, Sjoberg HE, Buchr E. Calcium homeostasis in normal pregnancy and puerperium. Acta Obstet Gynecol Scand 73:393–398, 1994.PubMedGoogle Scholar
  41. 41.
    Pirkin RM, Reynolds WA, Williams GA, Hargis GK. Calcium metabolism in normal pregnancy: a longitudinal study. Am J Obstet Gynecol 133:781–790, 1979.Google Scholar
  42. 42.
    Saggese G, Bertelloni S, Baroncelli GI, Pelletti A, Benedetti U. Evaluation of a peptide family encoded by the calcitonin gene in selected healthy pregnant women. Horm Res 34:240–244, 1990.PubMedCrossRefGoogle Scholar
  43. 43.
    Bugalho MJ, Lacerda AJF, Santos MA, Sobrinho LG, Cabaço JM. Serum calcitonin in pregnant women determined by a two-site immunoradiometric assay using monoclonal anti-peptide antibodies. Arq Med 12:4–5, 1998.Google Scholar
  44. 44.
    Lee RC, Walters JA, Reyland ME, Anderson SM. Constitutive activation of the prolactin receptor results in the induction of growth factor-independent proliferation and constitutive activation of signaling molecules. J Biol Chem 274:10024–10034, 1999.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2006

Authors and Affiliations

  • Patricia Costa
    • 1
  • Ana Luísa Catarino
    • 2
  • Fernanda Silva
    • 2
  • Luís G. Sobrinho
    • 3
  • Maria João Bugalho
    • 1
    • 3
    Email author
  1. 1.Centro de Investigação de Patobiologia MolecularInstituto Português de Oncologia de Lisboa Francisco Gentil E.P.E.LisboaPortugal
  2. 2.Departmento de Patologia MorfológicaInstituto Português de Oncologia de Lisboa Francisco Gentil E.P.E.LisboaPortugal
  3. 3.Serviço de EndocrinologiaInstituto Portuguès de Oncologia de Lisboa Francisco Gentil E.P.E.LisboaPortugal

Personalised recommendations